127 related articles for article (PubMed ID: 15622611)
1. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).
Mayles WP; Moore AR; Aird EG; Bidmead AM; Dearnaley DP; Griffiths SE; Warrington AP;
Radiother Oncol; 2004 Nov; 73(2):199-207. PubMed ID: 15622611
[TBL] [Abstract][Full Text] [Related]
2. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.
Mason MD; Moore R; Jones G; Lewis G; Donovan JL; Neal DE; Hamdy FC; Lane JA; Staffurth JN;
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e92-e100. PubMed ID: 27425582
[TBL] [Abstract][Full Text] [Related]
4. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
[TBL] [Abstract][Full Text] [Related]
5. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
[TBL] [Abstract][Full Text] [Related]
6. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
Haworth A; Kearvell R; Greer PB; Hooton B; Denham JW; Lamb D; Duchesne G; Murray J; Joseph D
Radiother Oncol; 2009 Mar; 90(3):299-306. PubMed ID: 19017549
[TBL] [Abstract][Full Text] [Related]
7. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
8. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
9. A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.
Moore AR; Warrington AP; Aird EG; Bidmead AM; Dearnaley DP
Radiother Oncol; 2006 Jul; 80(1):82-5. PubMed ID: 16828908
[TBL] [Abstract][Full Text] [Related]
10. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
[TBL] [Abstract][Full Text] [Related]
11. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
[TBL] [Abstract][Full Text] [Related]
12. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
13. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer.
Clark CH; Miles EA; Urbano MT; Bhide SA; Bidmead AM; Harrington KJ; Nutting CM;
Br J Radiol; 2009 Jul; 82(979):585-94. PubMed ID: 19332518
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer.
Amer AM; Mott J; Mackay RI; Williams PC; Livsey J; Logue JP; Hendry JH
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):199-207. PubMed ID: 12694839
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uniform dose (EUD) with respect to the rectal wall volume parameter.
Schwarz M; Lebesque JV; Mijnheer BJ; Damen EM
Radiother Oncol; 2004 Nov; 73(2):209-18. PubMed ID: 15542168
[TBL] [Abstract][Full Text] [Related]
16. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy.
Smeenk RJ; van Lin EN; van Kollenburg P; Kunze-Busch M; Kaanders JH
Radiother Oncol; 2009 Oct; 93(1):131-6. PubMed ID: 19523704
[TBL] [Abstract][Full Text] [Related]
17. The rush to judgment: Does the evidence support the enthusiasm over three-dimensional conformal radiation therapy and dose escalation in the treatment of prostate cancer?
Levitt SH; Khan FM
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):871-9. PubMed ID: 11704309
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated 3D conformal radiotherapy in prostate cancer.
Malone S
Expert Rev Anticancer Ther; 2004 Aug; 4(4):663-8. PubMed ID: 15270669
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
[TBL] [Abstract][Full Text] [Related]
20. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.
Coen JJ; Bae K; Zietman AL; Patel B; Shipley WU; Slater JD; Rossi CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1005-9. PubMed ID: 20932675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
